What the Best Longevity Panels Actually Test — and What Gets Left Out

You've booked the appointment. You've paid for the panel. You get back a 40-page PDF, flag your high LDL, notice your vitamin D is low, and that's about it. A few months later you're back on the same treadmill. If that loop sounds familiar, you're describing the experience of most people who enter longevity medicine through conventional lab testing. The information is there. The interpretation, the prioritisation, and the follow-through usually aren't.

That gap is where 2026 longevity protocols are competing — and where the real differences between a $200 annual physical and a $3,000-plus longevity programme become either obvious or invisible.

---

What a Modern Longevity Panel Actually Contains

The standard metabolic panel your GP orders is not a longevity panel. A genuine longevity-oriented workup includes several layers that standard care skips entirely.

Cardiovascular precision goes beyond total cholesterol. ApoB — apolipoprotein B, which measures the total number of atherogenic particles — is now the marker most cardiovascular specialists consider superior to LDL-C for predicting risk. The longevity medicine target for ApoB is below 60 mg/dL, compared to the American Heart Association's standard clinical threshold of under 100 mg/dL. That 40-point difference in targets has direct implications for whether a patient gets treated.

Inflammatory burden is tracked through high-sensitivity CRP — the longevity target is below 0.5 mg/L, not the standard clinical cutoff of 3 mg/L — along with IL-6, homocysteine, and fibrinogen. Metabolic health gets captured through fasting insulin, which is routinely excluded from standard panels despite being more predictive of insulin resistance than fasting glucose alone. A fasting insulin above 7 µIU/mL is flagged by longevity physicians as a concern worth addressing even when fasting glucose reads normal.

Biological age markers include GrimAge and PhenoAge clock calculations derived from methylation data, DHEA-S as a hormonal age proxy, and IGF-1. Telomere length testing appears on some panels; its clinical utility remains contested enough that most longevity physicians treat it as supplementary rather than primary data.

---

The Pricing Reality in 2026

Biomarker panels vary enormously in scope and cost. Quest Diagnostics and LabCorp both offer cardiovascular risk panels that include ApoB and Lp(a) for under $150 out of pocket. A methylation-based biological age test — the kind that produces an epigenetic clock output — runs between $299 and $499 depending on the provider, with TruDiagnostic and Elysium both active in this space.

Comprehensive longevity programmes that bundle testing with interpretation and protocol design are a different category. Programmes like System Labs or Yucca Health sit closer to the $1,500–$4,000 annual range, covering labs, physician review, and ongoing protocol management. For in-person depth, longevity clinics in Los Angeles frequently offer integrated panels at the higher end of that range with direct clinical access built in.

The relevant question isn't whether the cost is high — it's whether interpretation is included and whether the protocol that follows the labs is specific rather than generic.

---

What Most Panels Still Miss

Even panels priced above $2,000 have consistent blind spots.

Continuous metabolic data. A fasting glucose tells you where you are on one morning. Continuous glucose monitoring data over 14 days tells you how your metabolism responds to food, stress, and sleep. CGM devices are available without prescription for under $80 per two-week sensor in 2026, yet most panels still don't require or incorporate the data.

Sleep and HRV as biomarkers. The WHOOP and Oura-derived metrics that longevity-oriented patients already collect rarely get formally integrated into clinical panel interpretation. Some programmes are beginning to fold wearable-derived data into their baselines. Most haven't.

Gut microbiome composition. Viome and Biomesight both offer stool microbiome sequencing in the $99–$249 range, but formal clinical integration — where a physician actually adjusts a protocol based on results — remains rare outside specialist practices.

Hormonal granularity. Free testosterone, SHBG, free T3, and reverse T3 are routinely excluded from panels that claim to be comprehensive. Total testosterone without SHBG is close to useless for anyone trying to understand their androgenic status.

---

Where Peptides and Adjunct Therapies Fit In

A biomarker panel is only useful if it informs action. Panels increasingly drive specific interventions: low IGF-1 triggering a conversation about peptide therapy, elevated homocysteine prompting methylated B-vitamin dosing, declining NAD+ metabolites flagging a candidate for NAD+ supplementation or infusion.

The research backing is uneven. NAD+ precursor supplementation has solid mechanistic rationale from work by Sinclair et al. and has been studied in human trials, though most are small — the 2022 Elysium/Columbia trial ran 60 participants over 8 weeks, which is insufficient for definitive conclusions. GLP-1 receptor agonists have been incorporated into some longevity protocols for metabolic optimisation beyond weight management, with cardiovascular outcome data from the SELECT trial (2023, 17,604 participants) showing a 20% reduction in major adverse cardiovascular events independent of weight loss.

If you're evaluating options, the longevity clinics directory and broader online longevity programs are useful starting points for comparing what's included before you commit.

---

What to Actually Demand From Your Panel

If you're paying for a longevity protocol in 2026 and it doesn't include ApoB, Lp(a), fasting insulin, hs-CRP, DHEA-S, free testosterone with SHBG, free T3, and at minimum a methylation-based biological age calculation, you have a comprehensive metabolic panel with better marketing, not a longevity panel.

The meaningful differentiator isn't the length of the test menu. It's whether the practitioner reviewing results can connect a specific finding to a specific intervention, can explain the target ranges they're using and why, and retests the relevant markers at the appropriate interval — 90 days for metabolic and inflammatory markers, 6–12 months for epigenetic age.

The panel isn't the protocol. It's just the beginning of one.

---

Peptide Clinic Finder is a comparison platform. The author may receive compensation if you sign up through links on our partner pages.

---